Recent Company News

• 10:55 PM ET May 08, 2025
  

  Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

• 04:19 PM ET Mar 20, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:06 AM ET Apr 14, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 04:14 PM ET Apr 11, 2025
  

  Adaptimmune Therapeutics downgraded to hold from buy at Jones ($0.22, 0.00)

• 04:43 PM ET Mar 24, 2025
  

  Adaptimmune Therapeutics discloses loan prepayment of $25.0M - 8-K ($0.28, 0.00)

• 10:07 AM ET Mar 20, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (60 total)

• 07:12 AM ET Mar 20, 2025
  

  Adaptimmune Therapeutics reports Q4 cash and cash equivalents $91.1M, (37%) vs year-ago $144.0M; substantial doubt about ability to continue as going concern ($0.45, 0.00)

• 07:01 AM ET Mar 20, 2025
  

  Adaptimmune Provides Q4 and Full Year 2024 Business Update

• 04:56 PM ET Mar 12, 2025
  

  Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025